Substituted Heteroarylpiperidine Derivatives As Melanocortin-4 Receptor Modulators

  • Published: Jul 28, 2010
  • Earliest Priority: Jan 14 2009
  • Family: 2
  • Cited Works: 24
  • Cited by: 0
  • Cites: 7
  • Additional Info: Cited Works Published
Full-text?

The full document isn't yet available to us from the patent office.

Abstract

The present invention relates to substituted heteroarylpiperidine derivatives as melanocortin-4 receptor modulators, in particular as melanocortin 4 receptor antagonists. The antagonists are useful for the treatment of disorders and diseases such as cachexia induced by e.g. cancer, chronic kidney disease (CKD) or chronic heart failure (CHF), muscle wasting, anorexia induced by e.g. chemotherapy or radiotherapy, anorexia nervosa, amyotrophic lateral sclerosis (ALS), pain, neuropathic pain, anxiety and depression, nausea and emesis.


Claims

Information currently unavailable.

Download PDF
Document Preview
Document History
  • Publication: Jul 28, 2010
  • Application: Jan 14, 2009
    EP EP 09000437 A
  • Priority: Jan 14, 2009
    EP EP 09000437 A

Download Citation


Sign in to the Lens

Feedback